Charles River Laboratories Chairman James Foster Has Filed 3,711 Insider Transactions — Selling $266M and Buying $2M
James Foster, longtime chairman and former CEO of Charles River Laboratories, has filed 3,711 insider transactions since 2003, selling $266 million and purchasing $2 million in CRL stock.
James Foster, chairman and former CEO of Charles River Laboratories (CRL), has filed 3,711 insider transactions since 2003 — selling $266 million and purchasing $2 million in company stock. His 3,711 filings make him one of the most prolific insider filers in the life sciences and contract research sector, reflecting over two decades of leadership at the company he built into a global pre-clinical services powerhouse.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $266 million |
| Career Buy Value | $2 million |
| Total Transactions | 3,711 |
| Last Transaction | May 30, 2025 |
| Companies Filed Under | 1 |
What It Means
Foster led Charles River Laboratories for over 20 years as CEO before transitioning to executive chairman. Under his leadership, CRL grew from a niche provider of laboratory animals into a $10 billion contract research organization serving pharmaceutical and biotech clients worldwide. His $266 million in career sales represents systematic monetization typical of long-tenured executives, while his $2 million in career purchases signals selective conviction at points when he believed the stock was undervalued.
The 3,711 transaction count is exceptionally high even by prolific-filer standards. This reflects CRL's compensation structure, which generates frequent small filings through quarterly equity awards, vesting schedules, and dividend reinvestment plans. Foster's selling pattern has been remarkably consistent — small blocks sold at regular intervals through pre-arranged trading plans, without the concentrated bursts that would indicate discretionary timing.
What to Watch
- Whether Foster adds to his $2 million in career purchases at current CRL prices near $150 — well below the stock's 2021 peak of $460
- Charles River's recovery from the biotech funding downturn that pressured demand for pre-clinical research services
- Any changes to Foster's role or compensation structure as the company continues its leadership transition, which could materially alter his filing pattern
Related Research
Explore all researchNWF Advisory Services built a blended portfolio in Q4 2025: Berkshire for quality, XLK for tech beta, VOO and IVV for benchmark exposure, and a fast-rising Micron line for a more specific semiconductor view.
Mar 6, 2026
Ovata Capital's Q4 2025 filing is one of the strangest and most revealing in the cycle: Spotify calls at the top, Ryanair and TSMC right behind, IBIT in the top four, and multiple option-heavy special-situation lines throughout the book.
Mar 6, 2026
TD Capital Management kept ITOT, VTI, BSV, and IVV at the center of the book, but Q4 2025 still carried a tactical growth message: Netflix up 881%, ServiceNow up 449%, Oracle up 274%.
Mar 6, 2026
SHP Wealth Management's Q4 2025 13F is one of the clearest ETF-model portfolios in the dataset: VOO at 27.4%, income and duration sleeves in the top five, and no meaningful stock-picking noise at the top.
Mar 6, 2026
Bank of Hawaii still runs a massive ETF-heavy allocation book, but Q4 2025 added a visible growth sleeve: a new QQQ line, Netflix up 1,082%, and fresh single-stock adds around a global-beta core.
Mar 6, 2026